The company decided this after the Keytruda-Yervoy combination did not improve overall survival or progression-free survival compared to Keytruda monotherapy.
The Phase I/II trials will study Reqorsa in combination with Merck's Keytruda and AstraZeneca's Tagrisso in certain molecularly defined lung cancer subgroups.
The study will assess the safety and anti-tumor activity of the IL-7 agent and the checkpoint inhibitor combination for patients with PD-L1-expressing NSCLC.
The firm said that adjuvant nivolumab had benefitted patients regardless of PD-L1 expression, and that the company will submit the data to regulatory agencies.
Data from ESMO positioned the competing checkpoint inhibitors as potential new standards of care in the first-line setting, but biomarker questions remain.
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
